- Home
- RNXT vs FBIO Comparison
RNXT vs FBIO Comparison
Compare RNXT & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- FBIO
- Stock Information
- Founded
- RNXT 2012
- FBIO 2006
- Country
- RNXT United States
- FBIO United States
- Employees
- RNXT N/A
- FBIO N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- FBIO Health Care
- Exchange
- RNXT Nasdaq
- FBIO Nasdaq
- Market Cap
- RNXT 44.6M
- FBIO 53.5M
- IPO Year
- RNXT 2021
- FBIO N/A
- Fundamental
- Price
- RNXT $1.14
- FBIO $1.82
- Analyst Decision
- RNXT Strong Buy
- FBIO Strong Buy
- Analyst Count
- RNXT 2
- FBIO 2
- Target Price
- RNXT $7.25
- FBIO $21.00
- AVG Volume (30 Days)
- RNXT 107.8K
- FBIO 154.9K
- Earning Date
- RNXT 08-14-2025
- FBIO 08-19-2025
- Dividend Yield
- RNXT N/A
- FBIO N/A
- EPS Growth
- RNXT N/A
- FBIO N/A
- EPS
- RNXT N/A
- FBIO N/A
- Revenue
- RNXT $240,000.00
- FBIO $57,784,000.00
- Revenue This Year
- RNXT $3,104.65
- FBIO $51.59
- Revenue Next Year
- RNXT $301.89
- FBIO $44.74
- P/E Ratio
- RNXT N/A
- FBIO N/A
- Revenue Growth
- RNXT N/A
- FBIO N/A
- 52 Week Low
- RNXT $0.75
- FBIO $1.33
- 52 Week High
- RNXT $1.69
- FBIO $2.36
- Technical
- Relative Strength Index (RSI)
- RNXT 33.69
- FBIO 43.55
- Support Level
- RNXT $1.23
- FBIO $1.77
- Resistance Level
- RNXT $1.28
- FBIO $2.02
- Average True Range (ATR)
- RNXT 0.06
- FBIO 0.08
- MACD
- RNXT -0.01
- FBIO -0.01
- Stochastic Oscillator
- RNXT 15.00
- FBIO 20.00
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.